{
    "nctId": "NCT02806544",
    "briefTitle": "Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country",
    "officialTitle": "Neoadjuvant Endocrine Therapy in Locally Advanced Hormone Receptor Positive Breast Cancer in a Low-Resource, Middle-Income Setting (Guatemala)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 35,
    "primaryOutcomeMeasure": "Number of Participants Who Were Successfully Accrued in the Study, as a Measure of Feasibility",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient evaluated and treated at INCAN\n* Patients must provide informed consent\n* Patient must be \u2265 18 years of age.\n* Life expectancy \u2265 6 months\n* Clinical locally advance breast cancer (Stage IIB or III)\n* Pathologically confirmed diagnosis of estrogen receptor (ER)-positive or progesterone receptor (PR)-positive breast cancer with ER or PR Allred Score \\> 4\n* Patient must have an ECOG Performance Status of 0-2\n* Patients must be able to swallow and retain oral medication\n\nExclusion Criteria:\n\n* Patient must not have received any prior chemotherapy, radiation therapy, or biologic therapy for invasive breast cancer within the past five years\n* Patient must not be pregnant or nursing\n* Patient must not have had any prior malignancy except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for five years.\n* Women of childbearing age unable or unwilling to use contraception",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}